Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ic Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-302168S Tablets in Overweight/Obese Subjects After Multiple Oral Administration

NCT06541730 is registered in ClinicalTrials.gov with Chendu DIAO Pharmaceutical Group CO., LTD. as lead sponsor.

NCT NCT06541730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06541730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ic Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DA-302168S Tablets in Overweight/Obese Subjects After Multiple Oral Administration
Lead sponsor
Chendu DIAO Pharmaceutical Group CO., LTD.
Phase
Phase 1
Overall status
Completed
Start date
August 30, 2024
Completion date
January 30, 2025
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity